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Background: Patients’ perception of risk and their lifestyle choices are of major importance in the treatment of
common chronic diseases. This study reveals determinants for and knowledge about why people accept or reject
preventive medical interventions against heart disease.
Methods: A representative sample of 40-60-year-old Danish inhabitants was invited to participate in a web-based
survey. The respondents were presented with a hypothetical scenario and asked to imagine that they were at an
increased risk of heart disease, and subsequently presented with an offer of a preventive medical intervention. The
aim was to elicit preference structures when potential patients are presented with different treatment conditions.
Results: About one third of the respondents were willing to accept preventive medical treatment. Respondents
with personal experience with heart disease were more likely to accept treatment than respondents with family
members with heart disease or no prior experience with heart disease. The willingness to accept treatment was
similar for both genders, and when adjusting for experience with heart disease, age was not associated with
willingness to accept treatment. Socioeconomic status in terms of lower education was positively associated with
acceptance. The price of treatment reduced willingness to accept for the lower income groups, whereas it had no
effect in the highest income group. Some 57% of respondents who were willing to accept treatment changed their
decision following information on potential side effects.
Conclusions: In accordance with our pre-study hypothesis, individuals with low income were more sensitive to
price than individuals with high income. Thus, if the price of preventive medication increases above certain limits,
a substantial proportion of the population may refrain from treatment. More than half of the respondents who were
initially willing to accept treatment changed their decision when informed about the presence of potential side
effects. This is an important observation in relation to risk communication, since most side effects occur very
seldom, and a skewed assessment of treatment efficacy compared to risk of side effects may refrain some patients
from treatment. Thus, more research is needed to better allow patients to compare treatment efficacy with risk of
side effects in quantitative terms.
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Vast resources are spent on developing new treatment
regimes, but if patients are unwilling to accept or adhere
to the treatment, the investment will have been in vain.
Patients’ perception of risk and their lifestyle choices are
of major importance for prevention and early treatment
of common chronic diseases, such as type 2 diabetes,
hypertension and chronic obstructive lung disease, where
clinical health effects are often few or absent in the early
stages of the disease. Acceptance is seen as the initial deci-
sion by the patient to accept a treatment plan, adherence
is whether the patient actually begins medication or life-
style change, and persistence is whether the patient con-
tinues an agreed treatment plan for a longer period of
time. The present study will enhance knowledge about
possible determinants for acceptance and rejection of pre-
ventive interventions related to medical treatment.
Chronic diseases represent a significant burden to so-
ciety in terms of number of patients and treatment costs.
Lifestyle diseases are expected to account for 70% of all
chronic diseases by 2020, and it has been estimated that
lifestyle changes and medical interventions can prevent
or delay 80% of all heart diseases, strokes and cases of
diabetes, and 40% of all cancers [1]. Clinical experience,
however, suggests that lack of adherence significantly re-
duces the efficacy of such preventive interventions [2-4].
In a long-term study on persistence of statin use, persist-
ence was evaluated separately in patients without clinical
indications for cardiovascular disease (primary preven-
tion, n = 136 000) and in patients with coronary artery
disease (secondary prevention, n = 94 000) [5]. This
study demonstrated that persistence was significantly
lower for the primary prevention group (45%) compared
to the secondary prevention group (59%). In both groups
more than 75% of the patients stopped taking statins
within 2 years [5]. Comparable numbers have been ob-
served in other studies on persistence of statin use, and
predictors of poor long-term persistence included older
age, cardiovascular morbidity, and low income [6].
Preventive interventions strongly depend on the ability
and inclination of an individual to accept and adhere to an
agreed medical treatment. Studies based on the health be-
lief model have demonstrated that beliefs, concerns, and
perceived necessity of treatment play an important role in
adherence [7]. Patients’ acceptance is likely to drive their
behaviour towards their treatment, i.e. their adherence
and persistence. Thus, acceptance differs from adherence,
as it predicts the patient’s behaviour, while adherence is
the patient’s current behaviour towards their treatment
[8]. This indicates that measuring patients’ acceptance is
likely to predict their later adherence and persistence with
treatment.
Willingness to accept preventive medications and ad-
herence to treatment depend on how the person at riskperceives benefits, potential side effects, costs, as well as
interactions between these factors [8,9]. Reluctance to
accept and adhere to a treatment may appear particularly
tempting when the investment (e.g. money or use of pre-
ventive medication) is needed in the near future, whereas
the health gains are incurred as a risk reduction years
ahead [4,10]. Time lost due to frequent GP visits may also
be seen as a treatment-related cost for the patient.
Investment in education is likely to be associated with
a low discount rate (time preference) as it is associated
with present investment (costs) and gains in the distant
future [11]. This resembles the choice scenario for a pre-
ventive treatment like the one in the present study –
merely in the context of health investment. Under the
premise that time preference rates are similar in the
context of health and education one may expect that
individuals with higher education are more willing to
accept/invest in a preventive treatment. Although empir-
ical work by van der Pol [12] suggests that the time pref-
erence rates across these settings may be quite different,
it is the ex ante hypothesis of this paper that respon-
dents with higher levels of education are more likely to
invest in future health, and that this association is likely
driven by a lower time preference rate amongst those
who are highly educated.
Besides personal experience with a given disease, know-
ledge and experience of family members and friends have
previously been shown to correlate with adherence [in
10]. A more recent interview-based survey on hypothetical
scenarios confirmed that personal experience with cardio-
vascular disease affected the acceptance of medication,
whereas this was not the case if family members had expe-
rienced a cardiovascular disease [13]. However, the latter
study included non-symptomatic risk factors for heart dis-
ease (e.g. hypertension, hypercholesterolemia), which may
have diluted the degree of concern and therefore the in-
clination to accept treatment.
Identifying the potential for societal welfare gains from
disease prevention requires an understanding of what
people at risk value when making their choices, and why
they value certain factors more than others. The most
important determinants of health are related to individ-
ual behaviour, including individuals’ choices and trade-
offs that may significantly affect their health [14,15].
The hypothesis in the present study is that willingness to
accept a preventive treatment of heart disease is influenced
by cost, experience with heart disease, age, educational at-
tainment, frequency of needed control visits to the GP, and
the presence of potential side effects from the treatment.
The specific hypotheses are:
1. Individuals with personal or family-related experience
with heart disease are more willing to accept
treatment.
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the price of treatment than individuals with high
income.
3. Individuals with higher education are more willing
to accept/invest in a preventive treatment.
4. Increased frequency of control visits to the GP
reduces the willingness to accept treatment.
5. The decision to accept treatment is influenced by
the presence of a risk of side effects.
6. Individuals with personal experience with heart
disease are more willing to accept treatment despite
potential side effects than individuals with no prior
experience with heart disease.
Methods
Sample and setting
A representative sample of Danish speaking inhabitants
of Denmark aged 40–60 years were invited to participate
in the survey. In the survey, the respondents were pre-
sented with a hypothetical scenario and asked to imagine
that they were at an increased risk of heart disease, and
subsequently presented with an offer of a preventive med-
ical intervention targeted at reducing the risk of heart dis-
ease. Treatment benefit was given as an absolute risk
reduction (from 10% to 5%). The aim was to elicit prefer-
ence structures when potential patients are presented with
different treatment conditions.
Data were collected through a web-based question-
naire using TNS Gallup’s web-panel GallupForum. The
survey ran between 15 and 22 March 2012. Among the
panel members who accessed the website, 91% answered
the questionnaire. The age group from 40–60 years was
considered relevant for first time users of preventive
therapy against cardiovascular disease.
According to the Act on a Biomedical Research Ethics
Committee System, the project was not a biomedical re-
search project and therefore did not need the ethic com-
mittee’s approval.
Questionnaire
The questionnaire included a description of a risk sce-
nario together with 12 questions concerning health, life-
style and willingness to accept treatment under various
conditions, plus a number of questions on sociodemo-
graphic characteristics (gender, age, self-rated health status,
highest educational attainment, and household income).
The present paper focuses on the four questions related to
willingness to accept a treatment and personal experience
with heart disease (see section on Extract of questionnaire).
The two initial questions (regarding self-rated health and
experience with heart disease (personal or in the family))
have been used in previous studies [13], whereas the latter
two were specifically developed for this study. Prior to be-
ing presented to the web-panel, the entire questionnairewas evaluated regarding comprehensibility, relevance, ac-
ceptability and feasibility, and pilot tested by TNS Gallup.
Two variables on treatment conditions (price of medica-
tion and frequency of visits to the GP) were varied over
three levels. Each respondent was presented with only
one treatment option when asked whether he or she
would accept the treatment (see section on Extract of
questionnaire). The design was fully factorial, which
means that the impact of the two types of costs can be ana-
lysed independently.
Extract of questionnaire






2. Do you have knowledge of any heart disease of your
own or within your family?
a. Yes, I have a heart disease myself
b. Yes, I have had a heart disease myself
c. Yes, there are others in my family who have or
have had a heart disease
d. No
Imagine that you are visiting your GP.
The GP tells you that you have an increased risk of
a heart disease even though you presently do not
experience any troublesome symptoms.
Your GP informs you that for one in ten persons
like you, the disease will develop and have serious
consequences for your health.
You cannot know beforehand whether you belong to
the small group (10%) who will get the heart disease,
or to the larger group (90%) who will not.
There is now a possibility of medical treatment.
The medicine is preventive, and you will need to
take it the rest of your life.
When you begin taking the medicine it will
immediately reduce your risk of serious heart disease
from 10% to 5%.
The medicine will cost you X DKK every month
(X = 100, 400, 700), and you will need to visit your
GP for control Y times (Y = 2 times per month,
1 time per month, 4 times per year).
3. Will you based on this information accept the offer
and begin preventive medical treatment?
a. Yes
b. No
Related to the use of the medicine some people will
for shorter or longer periods experience side effects
such as lack of appetite, dizziness, tiredness,
headache, and an increased tendency to sweat. Often






Age, mean (SD) 50.8 (5.8)





Health status, n (%)
Good/very good 668 (62.5)
Fair 325 (30.4)
Poor/very poor 75 (7.0)
Experience with heart disease, n (%)
Yes, have or have had myself 55 (5.3)
Yes, family member has had 245 (23.6)
No 739 (71.1)
Household income, n (%)
Low (<80,000 USD) 329 (34.2)
Medium 368 (38.2)
High (≥130,000 USD) 266 (27.6)
Education, n (%)
Low (≤ high school) 243 (22.9)
Medium 717 (67.5)
High (university degree) 102 (9.6)
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4. Will these side effects change your assessment




Multiple logistic regression was used to analyse effects
of gender, age, self-rated health status, experience with
heart disease, education, income, price of medication
and frequency of GP visits on willingness to accept treat-
ment. Further, the effects of gender, age, self-rated health
status, experience with heart disease and price of medica-
tion on continued willingness to accept treatment despite
potential side effects were analysed among respondents
initially accepting treatment. The analyses were adjusted
for price, gender, age and experience with heart disease.
The adjusted ORs are presented with 95% confidence in-
tervals. Tests for trends were conducted when appropri-
ate, i.e. for continuous and ordinal variables. Interactions
between education and, respectively, experience with heart
disease and self-rated health status were tested, as were
interactions between price and, respectively, gender, age,
experience with heart disease, self-rated health status,
and income; and interactions between frequency of visits
to the GP and, respectively, gender, age, experience with
heart disease, self-rated health, and working-status
(working/not working). Since the sensitivity to price dif-
fered depending on the income, the analyses on price
were stratified on income levels. All analyses were con-




Of the 1069 respondents, 49% were females, and the aver-
age age of respondents was 51 years (Table 1). The self-
rated health status was reported as good/very good by
62.5% of the respondents, fair by 30%, and poor/very poor
by 7%. Slightly more than 5% had or had had a heart dis-
ease, while 24% had experience with family members with
heart disease. Approximately 34% had a household in-
come below 500 000 DKK (<80 000 USD), while 28% had
a household income equal to or above 800 000 DKK
(≥130 000 USD). The degree of educational attainment
was classified into three categories with 23% having high
school as their highest educational attainment, and 10%
with at least a university degree (Table 1).
Acceptance versus sample characteristics
Of the 1069 respondents, 365 (34%) accepted treatment
before they were given information about potential side
effects (Table 2). Gender did not affect willingness toaccept treatment. Although the unadjusted analysis for
trend indicated that acceptance of treatment increased
with age (p = 0.03), the trend was no longer statistically
significant when the analysis was adjusted for gender,
prior experience with heart disease and price (p = 0.08)
(Table 2). Personal experience with heart disease signifi-
cantly affected the willingness to accept treatment (p <
0.01), whereas there was no difference in acceptance be-
tween respondents with no prior experience with heart
disease and respondents with family members with heart
disease (p = 0.17) (Table 2).
Neither self-rated health status nor household income
affected the willingness to accept treatment (Table 2).
Educational attainment significantly affected the willing-
ness to accept treatment (p = 0.01). A significant trend
of decreasing willingness to accept treatment with in-
creasing educational attainment was observed (p < 0.01,
following adjustment for price, gender, age, and experi-
ence with heart disease) (Table 2).
Table 2 Willingness to accept treatment versus participant characteristics
Accepting treatment
Accepting, n (%) ORcrude ORadj* (95%-CI) Test for trend
Total 365 (34.1) - - -
Gender p = 0.309 p = 0.760
Male 195 (35.6) (ref.) (ref.) -
Female 170 (32.6) 0.87 0.96 (0.74, 1.25)
Age groups p = 0.158 p = 0.421
40-44 52 (28.9) (ref.) (ref.) pcrude = 0.027
45-49 91 (32.7) 1.20 1.10 (0.72,1.68) padj =0.077
50-54 90 (33.7) 1.25 1.22 (0.80, 1.86)
55-60 132 (38.4) 1.53 1.39 (0.93, 2.08)
Health status p = 0.282 p = 0.813
Good/very good 216 (32.3) (ref.) (ref.) pcrude = 0.118
Fair 119 (36.6) 1.21 1.07 (0.79, 1.43) padj =0.529
Poor/very poor 29 (38.7) 1.31 1.16 (0.69, 1.97)
Experience with heart disease p < 0.001 p < 0.001
Yes, have or have had myself 35 (63.6) (ref.) (ref.) -
Yes, family member has had 87 (35.5) 0.31 0.33 (0.18, 0.62)
No 232 (31.4) 0.26 0.27 (0.15, 0.48)
Household income p = 0.429 p = 0.522
Low 114 (34.7) (ref.) (ref.) pcrude = 0.497
Medium 120 (32.6) 0.91 0.96 (0.69, 1.33) padj =0.428
High 100 (37.6) 1.14 1.16 (0.82, 1.65)
Education p = 0.037 p = 0.005
Low 96 (39.5) (ref.) (ref.) pcrude = 0.011
Medium 240 (33.5) 0.77 0.69 (0.50, 0.95) padj = 0.001
High 26 (25.5) 0.52 0.42 (0.24, 0.73)
*Adjusted for gender, age (four groups), experience with heart disease, price.
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price of treatment
The frequency of GP visits (2 times/month, 1 time/month,
or 4 times/year) did not affect overall treatment accept-
ance (p = 0.90) (Table 3).
Tests for interaction showed that none of the follow-
ing covariates interacted with frequency of check-ups at
the GP: working status (p = 0.24), gender (p = 0.40), age
(p = 0.16), health status (p = 0.17), experience with heart
disease (p = 0.50) (Table 3).
Tests for interaction between price and various covari-
ates with respect to the effect on willingness to accept
treatment were conducted (Table 3). The results showed
that household income interacted with price (p = 0.02),
while none of the following covariates interacted with
price: gender (p = 0.56), age (p = 0.99), self-rated health
status (p = 0.53), experience with heart disease (p = 0.69).
Further analyses on the effect of price on willingness to
accept treatment were stratified on household incomeand demonstrated that price had a stronger impact on
acceptance in the lower income groups (Table 3). For
the two lowest income groups, there were significant
trends of decreasing acceptance of the treatment when
the price of the treatment was increased. This trend was
not seen in the high income group (Table 3).
Acceptance in view of presence of potential side effects
following treatment
Among the 365 respondents accepting treatment in the
first place, 156 (43%) stated that the information on po-
tential side effect would not affect their original decision
of accepting treatment (Table 4). None of the covariates
considered had significant effect on continued acceptance
of treatment in view of potential side effects (Table 4).
Discussion
A study on prevalence and incidence of cardiovascular
disease in Denmark has shown that the prevalence of
Table 3 Willingness to accept treatment versus GP visits and price, stratified on household income
Accepting treatment
n (%)* ORcrude ORad (95%-CI) Test for trend
Rate of GP visits p = 0.905 p = 0.817**
2 per month 125 (35.1) (ref.) (ref.) pcrude = 0.676
1 per month 123 (33.9) 0.95 0.94 (0.68, 1.29)** padj = 0.529
4 per year 116 (33.5) 0.94 0.90 (0.65, 1.25)**
Low income
Price per month 49 (46.7) p < 0.001 p = 0.003***
DKK 100 (ref.) (ref.) pcrude < 0.001
DKK 400 44 (35.8) 0.63 0.56 (0.32, 1.00)*** padj = 0.001
DKK 700 21 (21.0) 0.30 0.32 (0.17, 0.62)***
Medium income
Price per month p = 0.052 p = 0.039***
DKK 100 50 (40.7) (ref.) (ref.) pcrude = 0.017
DKK 400 37 (30.8) 0.65 0.67 (0.39, 1.16)*** padj = 0.011
DKK 700 33 (26.4) 0.52 0.49 (0.28, 0.85)***
High income
Price per month p = 0.020 p = 0.071***
DKK 100 42 (44.7) (ref.) (ref.) pcrude = 0.645
DKK 400 22 (22.6) 0.43 0.47 (0.25, 0.91)*** padj = 0.558
DKK 700 36 (41.9) 0.89 0.85 (0.46, 1.57)***
*Number accepting treatment and percentage out of all subjects in the category.
**Adjusted for gender, age (four groups), experience with heart disease, in workforce, price.
***Adjusted for gender, age (four groups), experience with heart disease.
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close to 8% in men as well as women [16], which fits rea-
sonably well with our observation of 5.3% in the present
study, considering that our population was slightly youn-
ger. Data from the general Danish population (drawn from
Statistics Denmark) on average household income in the
present age group have previously been reported to be
approximately 100 000 USD, and close to 28% had high
school as their highest educational attainment, while
7% had an education longer than 18 years, correspond-
ing to a university degree [17]. This is in good agreement
with the composition of our study group and supports its
representativeness.
Persistence of statin use in primary prevention was
recently reported to be 45% among patients in treatment
[5]. Our respondents including both people with and
without experience with heart disease had an overall
acceptance rate of 34%. This low overall acceptance rate
may to some extent be generated by the effect measure
(an absolute risk reduction) applied in our study, as it
has previously been demonstrated that information given
in terms of absolute risk reduction is associated with
lower appreciation of a clinical effect than relative risk
reduction [17-19]. A more important reason when com-
pared to the study by Chodick et al. [5] is that this studyincluded patients in actual need of treatment, whereas the
overall acceptance rate in our sample mainly included re-
spondents with no personal experience with heart disease
placed in a hypothetical situation. This is supported by the
observation that respondents with personal experience
with heart disease had an acceptance rate of 64% com-
pared to 31% among those with no prior experience with
heart disease.
Age has previously been reported to affect persistence
in use of statins [6]. We observed this effect on accept-
ance of treatment in the crude results, but not after
adjusting for gender and prior experience with heart dis-
ease. Previous findings may not have adjusted for prior
experience with heart disease. The prevalence of heart
disease increases with age, and age is included as an
independent parameter in the Heart Score model used
clinically to visualize risk levels and to guide patients
and their GPs on initiating preventive treatment with
statins or equivalent products. As seen in the present
study, age may also in previous studies have acted as a
proxy for previous experience with heart disease, with-
out being independently associated with higher accept-
ance of treatment.
An interesting observation was that respondents with
secondhand experience with heart disease (a family member
Table 4 Continued acceptance of treatment in view of information on potential side effects
Continue to accept treatment despite side effects*
Accepting, n (%) ORcrude ORadj** (95%-CI) Test for trend
Total 156 (42.7) - - -
Gender p = 0.889 p = 0.832
Male 84 (43.1) (ref) (ref) -
Female 72 (42.4) 0.97 0.95 (0.62, 1.47)
Age groups p = 0.205 p = 0.257
40-44 18 (34.6) (ref) (ref) pcrude = 0.838
45-49 47 (51.7) 2.02 1.96 (0.96, 4.03) padj = 0.960
50-54 37 (41.1) 1.32 1.23 (0.60, 2.54)
55-60 54 (40.9) 1.31 1.38 (0.70, 2.74)
Health status p = 0.804 p = 0.682
Good/very good 95 (44.0) (ref) (ref) pcrude = 0.577
Fair 48 (40.3) 0.86 0.97 (0.43, 2.22) padj = 0.458
Poor/very poor 12 (41.4) 0.90 1.24 (0.59, 2.58)
Experience with heart disease p = 0.656 p = 0.609 -
Yes, have or have had myself 14 (40.0) (ref) (ref)
Yes, family member has had 34 (39.1) 0.96 0.81 (0.50, 1.31)
No 103 (44.4) 1.20 0.86 (0.38, 1.97)
Price p = 0.402 p = 0.401
DKK 100 69 (45.7) (ref) (ref) pcrude = 0.725
DKK 400 43 (37.7) 0.72 0.71 (0.43, 1.18) padj = 0.705
DKK 700 44 (44.4) 0.95 0.94 (0.56, 1.59)
*Among the 365 (34.1%) subjects who originally accepted treatment.
**Adjusted for gender, age (four groups), experience with heart disease, price.
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dents with no experience with heart disease. We had
expected their response to more closely resemble re-
spondents with personal experience with heart disease,
but apparently respondents did not draw on family mem-
bers’ experiences, when deciding to accept a personal
treatment offer. A parallel observation has been seen in
another recent study [13]. A possible explanation may be
different perceptions of baseline risk across the respond-
ent groups. For those with personal experience of heart
disease, the presented baseline risk is most likely deemed
irrelevant, as these patients perceive their risk to be sig-
nificantly higher. In contrast, respondents with family
members with known heart disease and potentially at in-
creased risk may feel relieved by a stated risk as low as 1
in 10, and therefore feel less inclined to accept treatment
in this theoretical scenario. This is not optimal as these
respondents are known to have a higher risk of getting
heart disease than others, and would potentially benefit
from either treatment or lifestyle changes. A recent study
in a setting with a spouse or parent being hospitalized sug-
gest that this setting is a better opportunity to induce
lifestyle changes among other family members [20].Our ex ante hypothesis regarding the association be-
tween education and acceptance levels was that those
with higher levels of education would exhibit lower time
preference rates, and thus a greater willingness to engage
in preventive health care. However, the results suggest
that those with higher levels of education are much less
willing to participate in the preventive programme. This
observation may partly be explained by the observation
from another study that time preference rates across dif-
ferent settings are highly uncorrelated (as suggested by
van der Pol [12]). A different explanation might be that
education is often associated with numeracy skills. Thus,
those with higher levels of education may be better at
understanding benefits given as percentages and there-
fore also at balancing risks against benefits. Perhaps only
respondents with higher levels of education understood
the benefit information sufficiently to realise that more
than 90% of all patients will gain no extra benefit from
the treatment.
In accordance with our pre-study hypothesis based on
an expected decreasing marginal utility of income at
higher income levels, the willingness to accept treatment
was affected by the price of the treatment. Individuals
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ment than individuals with high income. This effect was
present in the two lower income groups only. The price
range was realistic and chosen sufficiently wide to demon-
strate a possible effect of household income on the sensi-
tivity to price. The present study based on hypothetical
scenarios indicates that if the price of preventive medica-
tion increases above a certain threshold, a substantial pro-
portion of the population may refrain from treatment.
The actual threshold will depend on the income, and will
therefore depend on the societal context and setting. The
lowest monthly cost was equivalent to 80% of the minimal
wage in Denmark for one hour unskilled work, which is
about 120 DKK/hour.
We had hypothesised that the frequency of control
visits to the GP would affect acceptance of treatment.
This was not the case within the range of frequencies
chosen by the authors. We are not able to conclude
whether our respondents are generally insensitive to this
cost of treatment, do not regard it as a treatment cost,
or whether we have basically misjudged the frequency
range that would cause a stratification of our population.
Increasing the frequency of required visits to the GP
might cause some respondents to refrain from treatment,
but might also easily become clinically irrelevant. More-
over, for some people frequent visits to the GP may be
interpreted as a benefit because closer surveillance may
ensure detection of other risks, should they arise. An alter-
native explanation may be that the GP visits are inter-
preted as optional rather than mandatory.
Following the question on treatment acceptance based
on information on risk reduction, price of medication,
and frequency of GP visits, the respondents were faced
with the presence of a risk of certain specified side ef-
fects. Following the information on side effects, 43% of
the respondents who had accepted treatment answered
that they would not change their initial decision. These
respondents behave in line with a Cochrane review from
2008 stating that telling patients about adverse effects of
treatment did not significantly affect their adherence
[21], and a study on pain relief in osteoarthritis where
patients demonstrated a willingness to accept some add-
itional and specified risks to gain pain relief [22]. The
same study, however, also showed that some side effects
were regarded as more acceptable than others [22], and
a recent study by Baroletti et al. [23] indicated that even
fear of a potential side effect is an important factor for
non-adherence. A possible reason for the discrepancy
may be that the present study considers acceptance,
which as previously discussed is one step earlier than ad-
herence. Based on previous research on trade-offs be-
tween treatment effects and side effects [24], and a study
on unspecific side effects related to lipid-lowering medi-
cation [25], we deliberately described the potential sideeffects as sufficiently grave to divide our population. The
side effects may therefore appear slightly worse than
what could be expected from a drug intended for life-
long treatment to prevent a disease not clinically present
at the date of prescription. As slightly more than half of
our respondents changed their initial decision to accept
treatment in this hypothetical study, we succeeded in
finding a level of adverse effect that allowed for analyses
on potential determinants. We had expected that re-
spondents with personal experience with heart disease
or a poorer self-rated health status would accept treat-
ment despite side effects to a higher degree than respon-
dents with no prior experience with heart disease and
with higher self-rated health. However, our results dem-
onstrated that neither type of experience with heart dis-
ease nor low self-rated health status had a significant
effect on continued acceptance of treatment in view of
potential side effects. This is an important observation
that deserves more detailed research, since some side ef-
fects appear very early after initiating medication, some-
times even before therapeutic effects, and diminish over
time, whereas other side effects increase in frequency
and severity with increasing treatment time. Further,
most side effects very seldom occur, and a skewed as-
sessment of treatment efficacy compared to risk of
side effects may refrain some patients from treatment.
Thus, more research is needed on medical risk com-
munication to better allow patients to compare treat-
ment efficacy with risk of side effects in quantitative
terms.
Strengths and weaknesses
A strength of the present study is that data were collected
through the highly experienced organisation TNS Gallup
taking advantage of their web-panel GallupForum, which
is a validated data collection tool. Another strength is that
the response rate was high (91%) among panel members
who opened the web-based questionnaire. However, it is
possible that some selection bias was introduced in con-
nection with choosing to open the website at all. It is
therefore reassuring that our respondent group is repre-
sentative on sociodemographic characteristics. A further
important strength is that we applied a sample design that
was fully factorial with respect to the two treatment con-
dition factors, price of medication and frequency of GP
visits, which meant that the impact of the two types of
costs could be studied independently. A weakness might
be that no existing validated questionnaire suited the pur-
pose of this study. However, care was taken in construc-
tion of the questionnaire. It was of priority to keep it
short, and to ensure the questions were simple and unam-
biguous. In order to ensure that questions were under-
stood by the respondents, we had the questionnaire pilot
tested by Gallup.
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When presented with a hypothetical scenario, asked to
imagine being at an increased risk of heart disease, and
subsequently presented with an offer of a preventive
medical intervention targeted to reduce the risk of heart
disease, about one third of the study population was will-
ing to accept the treatment offer. Respondents with per-
sonal experience with heart disease were more likely to
accept treatment, while respondents with family members
with heart disease were no more likely to accept than sub-
jects with no prior experience with heart disease. The will-
ingness to accept treatment was similar for both genders,
and when adjusting for experience with heart disease,
age was not associated with willingness to accept treat-
ment. Socioeconomic status in terms of lower education
was positively associated with acceptance. The price of the
treatment reduced willingness to accept for the lower
income groups, whereas it had no effect in the highest in-
come group. The implication is that if the price of prevent-
ive medication increases above certain limits, a substantial
proportion of the population may potentially refrain
from treatment. Some 57% of respondents who were
willing to accept treatment changed their decision fol-
lowing information on potential side effects. This is an im-
portant observation in relation to risk communication,
since most side effects occur very seldom, and a skewed
assessment of treatment efficacy compared to risk of side
effects may refrain some patients from treatment. Thus,
more research is needed to better allow patients to com-
pare treatment efficacy with risk of side effects in quanti-
tative terms.
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